Nomura Asset Management Co. Ltd. Sells 8,217 Shares of Insulet Co. (NASDAQ:PODD)

Nomura Asset Management Co. Ltd. lowered its position in Insulet Co. (NASDAQ:PODD - Free Report) by 5.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 145,199 shares of the medical instruments supplier's stock after selling 8,217 shares during the quarter. Nomura Asset Management Co. Ltd. owned approximately 0.21% of Insulet worth $37,907,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. SBI Securities Co. Ltd. acquired a new stake in shares of Insulet in the fourth quarter worth about $36,000. Sumitomo Mitsui DS Asset Management Company Ltd lifted its holdings in Insulet by 30.1% in the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 8,395 shares of the medical instruments supplier's stock worth $2,192,000 after purchasing an additional 1,942 shares during the last quarter. Orion Portfolio Solutions LLC lifted its holdings in Insulet by 86.2% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 7,826 shares of the medical instruments supplier's stock worth $1,822,000 after purchasing an additional 3,623 shares during the last quarter. Stifel Financial Corp boosted its position in Insulet by 2.8% during the third quarter. Stifel Financial Corp now owns 10,527 shares of the medical instruments supplier's stock worth $2,450,000 after purchasing an additional 290 shares during the period. Finally, Ayrshire Capital Management LLC grew its holdings in Insulet by 34.6% during the fourth quarter. Ayrshire Capital Management LLC now owns 22,988 shares of the medical instruments supplier's stock valued at $6,001,000 after purchasing an additional 5,911 shares during the last quarter.

Remove Ads

Insulet Price Performance

Shares of PODD stock traded up $3.17 during trading hours on Wednesday, hitting $266.35. The company had a trading volume of 277,578 shares, compared to its average volume of 704,877. The firm's fifty day moving average is $271.17 and its 200 day moving average is $259.40. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The firm has a market capitalization of $18.70 billion, a price-to-earnings ratio of 46.00, a PEG ratio of 3.62 and a beta of 1.29. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $289.46.

Insulet (NASDAQ:PODD - Get Free Report) last posted its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.15. The business had revenue of $597.50 million for the quarter, compared to analyst estimates of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. On average, sell-side analysts predict that Insulet Co. will post 3.92 EPS for the current fiscal year.

Insider Buying and Selling at Insulet

In other Insulet news, Director Wayne A.I. Frederick sold 1,825 shares of the business's stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total value of $501,875.00. Following the completion of the transaction, the director now directly owns 3,231 shares of the company's stock, valued at approximately $888,525. The trade was a 36.10 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the sale, the executive vice president now directly owns 11,383 shares in the company, valued at $3,187,240. This trade represents a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.47% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on PODD. Raymond James reaffirmed an "outperform" rating and set a $328.00 price objective (up from $294.00) on shares of Insulet in a report on Friday, February 21st. JPMorgan Chase & Co. upped their price target on shares of Insulet from $280.00 to $330.00 and gave the company an "overweight" rating in a report on Thursday, December 12th. Piper Sandler lifted their price objective on Insulet from $285.00 to $310.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. Wells Fargo & Company raised their target price on Insulet from $305.00 to $322.00 and gave the company an "overweight" rating in a report on Friday, February 21st. Finally, Canaccord Genuity Group upped their price target on Insulet from $304.00 to $324.00 and gave the stock a "buy" rating in a report on Friday, February 21st. Four equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company's stock. According to MarketBeat, Insulet presently has a consensus rating of "Moderate Buy" and an average price target of $292.06.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.